Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore

被引:21
作者
Chau, Yi Ting [1 ]
Nashi, Nazrul [2 ]
Law, Lawrence Siu-Chun [1 ]
Goh, Raymond Kai Heng [3 ]
Choo, Selena Xueli [2 ]
Seetharaman, Santhosh Kumar [1 ]
机构
[1] Alexandra Hosp, 378 Alexandra Rd, Singapore, Singapore
[2] Natl Univ Singapore Hosp, Univ Orthopaed Hand & Reconstruct Microsurg Clust, 5 Lower Kent Ridge Rd, Singapore, Singapore
[3] Sengkang Gen Hosp, 110 Sengkang East Way, Singapore, Singapore
关键词
Osteoporosis; Hip fracture; Compliance; Persistence to treatment; HEALTH BELIEFS; FRAGILITY FRACTURE; INCIDENT FRACTURES; OLDER WOMEN; PREVENTION; MORTALITY; RISK; CARE; HOSPITALIZATION; METAANALYSIS;
D O I
10.1007/s11657-020-00816-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Undertreatment of osteoporosis after hip fracture increases the risk of death, disability, recurrent osteoporotic fractures, and financial burden. Only half were compliant with osteoporosis medications. Elderly patients were less persistent and compliant to treatment. Denosumab was associated with a higher proportion of days covered by osteoporosis medications than oral bisphosphonates. Purpose The aim of this study was to identify factors that contributed to the initiation of osteoporosis medications following hip fracture as well as the compliance and persistence to osteoporosis medications. Methods Clinical data of 532 patients older than 50 years old admitted for surgical fixation of hip fractures were reviewed. Three hundred forty-seven had sufficient data for analysis after excluding patients with non-fragility fractures. Prescription for any osteoporosis medication in the year following hip fracture as well as compliance to treatment was evaluated. Results Only 40.3% of patients were prescribed with osteoporosis medication within 1 year post-hip fracture. Females (p =0.020) performing dual-energy x-ray absorptiometry scan (p <0.001) and 25 hydroxyvitamin D levels testing post-hip fracture (p <0.027) were independent determinants of increased likelihood of being prescribed with osteoporosis medication. Patients with proportion of days covered (PDC) >= 0.8 (or 80% of days covered in a year) were defined as compliant. Overall, only 49.7% of the patients were compliant with osteoporosis medications. Elderly patients aged 70-79 years (p =0.002) and males (p =0.017) were less persistent with osteoporosis treatment when compared with patients aged < 69 years and females. The compliance was poorer in patients aged 70-79 years (p= 0.026) as compared with those under 69 years of age. Statistically significant difference (p =0.032) was observed between mean PDC of oral bisphosphonates (0.66) and denosumab (0.83). Only 39.3% of patients were persistent with treatment at 1 year. Conclusion Our findings demonstrate the urgent need to increase awareness through a structured protocol of osteoporosis treatment. A multi-disciplinary Fracture Liaison Service should be set up to ensure compliance to osteoporosis medication post-hip fracture.
引用
收藏
页数:10
相关论文
共 45 条
[1]   Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research [J].
Adler, Robert A. ;
El-Hajj Fuleihan, Ghada ;
Bauer, Douglas C. ;
Camacho, Pauline M. ;
Clarke, Bart L. ;
Clines, Gregory A. ;
Compston, Juliet E. ;
Drake, Matthew T. ;
Edwards, Beatrice J. ;
Favus, Murray J. ;
Greenspan, Susan L. ;
McKinney, Ross, Jr. ;
Pignolo, Robert J. ;
Sellmeyer, Deborah E. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (01) :16-35
[2]   Progressively Increasing Fracture Risk With Advancing Age After Initial Incident Fragility Fracture: The Tromso Study [J].
Ahmed, Luai Awad ;
Center, Jacqueline R. ;
Bjornerem, Ashild ;
Bluic, Dana ;
Joakimsen, Ragnar M. ;
Jorgensen, Lone ;
Meyer, Haakon E. ;
Nguyen, Nguyen D. ;
Nguyen, Tuan V. ;
Omsland, Tone K. ;
Stormer, Jan ;
Tell, Grethe S. ;
van Geel, Tineke A. C. M. ;
Eisman, John A. ;
Emaus, Nina .
JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (10) :2214-2221
[3]   Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy's fracture clinic screening program [J].
Beaton, D. E. ;
Dyer, S. ;
Jiang, D. ;
Sujic, R. ;
Slater, M. ;
Sale, J. E. M. ;
Bogoch, E. R. .
OSTEOPOROSIS INTERNATIONAL, 2014, 25 (01) :289-296
[4]   Gender inequalities in the treatment of osteoporosis [J].
Bor, Andrea ;
Matuz, Maria ;
Gyimesi, Nora ;
Biczok, Zsuzsanna ;
Soos, Gyoengyver ;
Doro, Peter .
MATURITAS, 2015, 80 (02) :162-169
[5]   Impact of Pharmacist-Physician Collaboration on Osteoporosis Treatment Rates [J].
Bowers, Brandi L. ;
Drew, Amy M. ;
Verry, Christian .
ANNALS OF PHARMACOTHERAPY, 2018, 52 (09) :876-883
[6]   Incidence and Mortality of Hip Fractures in the United States [J].
Brauer, Carmen A. ;
Coca-Perraillon, Marcelo ;
Cutler, David M. ;
Rosen, Allison B. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (14) :1573-1579
[7]  
Brown JP, 2002, CMAJ., V167, P1
[8]   Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study [J].
Brozek, W. ;
Reichardt, B. ;
Zwerina, J. ;
Dimai, H. P. ;
Klaushofer, K. ;
Zwettler, E. .
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (01) :387-396
[9]   Measuring and improving adherence to osteoporosis pharmacotherapy [J].
Cadarette, Suzanne M. ;
Burden, Andrea M. .
CURRENT OPINION IN RHEUMATOLOGY, 2010, 22 (04) :397-403
[10]  
Centers for Disease Control and Prevention, 2020, AD BOD MASS IND